Search

The article discusses the utility of sentinel lymph node biopsy (SLNB) in younger and older patients with melanoma, with Dixon and colleagues concluding that the procedure is not necessary for patients under 40 or over 60 years of age. The study raises concerns about the validity of the analytical approach and the conclusions drawn, particularly due to the mixing of different online platforms for estimation. Despite the study's findings, the article emphasizes the importance of SLNB in improving regional node control and disease-free survival for patients with melanoma, highlighting the need for individualized assessments of appropriate therapies. [Extracted from the article]